- Home
- CLLS vs EU Comparison
CLLS vs EU Comparison
Compare CLLS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | EU |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.5M | 464.5M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | EU |
|---|---|---|
| Price | $4.23 | $2.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | 102.1K | ★ 3.2M |
| Earning Date | 11-07-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | $44,142,000.00 |
| Revenue This Year | $32.58 | $17.41 |
| Revenue Next Year | $20.68 | $95.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $1.01 |
| 52 Week High | $5.48 | $4.19 |
Technical Indicators
Market Signals| Indicator | CLLS | EU |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 61.21 |
| Support Level | $4.37 | $2.35 |
| Resistance Level | $4.68 | $2.54 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 6.97 | 95.29 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.